January 4, 2021 -- Lantern Pharma is launching the development of an antibody-drug conjugate (ADC) program through an evaluation and potential development agreement with Califia Pharma.
Under the agreement, Lantern will leverage Califia's patent-protected linker library and conjugation processes and payloads, including Lantern's DNA damage-causing compounds (LP-100 and LP-184), for the development of ADC-based therapies for a range of solid tumors and blood cancers. Lantern will also utilize its proprietary artificial intelligence platform, RADR, to determine the types of cancer, targets, and cancer biomarker signatures matched to this ADC approach.
The ADC program will initially focus on evaluated Califia's linker technology with DNA damaging small molecules in select solid tumors. The companies will optimize target indications and design during 2021, with the intent to launch investigational new drug and clinical programs in 2022.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
